Josep M. Piulats - Publications, H-index & Citations

Josep M. Piulats

Hospitalet de Llobregat

49H指数

425论文数

1.5W被引数

收录论文 98

发表时间

[177Lu]Lu-PSMA-617 in patients with PSMA-positive metastatic androgen pathway modulator-naive/sensitive prostate cancer (PSMAddition): a phase 3 randomised, controlled trial [177Lu]Lu-PSMA-617在PSMA阳性转移性雄激素通路调节剂初治/敏感的前列腺癌患者中的应用（PSMAddition）：一项3期随机对照试验

The Lancet

IF88.5

2026-08-06

PREAI

Scott T Tagawa; Oliver Sartor; Josep M Piulats; Fred Saad; Karim Fizazi; Alison Reid; Himisha Beltran; Gero Kramer; Hakim Mahammedi; Matthias Eiber; Shilpa Gupta; Daniel Castellano; Ralph Hauke; Hyun Kim; Cheol Kwak; See Tong Pang; Philippe Barthélémy; Dong Dai; Jae Lyun Lee; Luke Nordquist

PROSTATE-SPECIFIC ANTIGEN ENDPOINTS IN THE PHASE 3 PSMADDITION STUDY OF [177LU]LU-PSMA-617 (177LU-PSMA-617) COMBINED WITH ADT AND ARPI IN PATIENTS WITH PSMA-POSITIVE (PSMA plus ) METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC)前列腺特异性抗原终点在[177Lu]Lu-PSMA-617（177Lu-PSMA-617）联合ADT和ARPI治疗PSMA阳性（PSMA plus）转移性激素敏感型前列腺癌（MHSPC）的PSMADDITION III期研究中的表现

Journal of Urology

IF6.8

2026-05-01

PREAI

Saad, Fred; Tagawa, Scott T.; Sartor, Oliver; Fizazi, Karim; Reid, Alison; Beltran, Himisha; Piulats, Josep M.; Kramer, Gero; Mahammedi, Hakim; Eiber, Matthias; Gupta, Shilpa; Kwak, Cheol; Pang, See Tong; Rigaud, Jerome; Bardot, Stephen; Shore, Neal; Bouillaud, Emmanuel; Sakharova, Olga; Morris, Michael J.

SAFETY OF RUCAPARIB VS DOCETAXEL OR SECOND-GENERATION ANDROGEN RECEPTOR PATHWAY INHIBITOR THERAPY FOR PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AND A BRCA MUTATION IN TRITON3 鲁卡帕利与多西他赛或第二代雄激素受体通路抑制剂治疗携带BRCA突变的TRITON3试验中转移性去势抵抗性前列腺癌患者的安全性比较

Journal of Urology

IF6.8

2026-05-01

PREAI

Gingerich, Joel R.; Bryce, Alan H.; Fizazi, Karim; Ryan, Charles J.; Chowdhury, Simon; Mellado, Begona; Misleh, Jamal; Peer, Avivit; Pfister, David; Rowe, Julie; Tagawa, Scott; McDermott, Ray; Piulats, Josep M.; Sridhar, Srikala S.; Abida, Wassim; Pliskin, Marc; Murphy, Susie; Hansen, Natalie; Pintus, Elias

Comment on: “Tebentafusp Versus Nivolumab Plus Ipilimumab for Metastatic Uveal Melanoma: An E‑Value Sensitivity Analysis Assessing Effect of Unmeasured Confounders on Observational Associations”评述：“Tebentafusp 与 Nivolumab 联合 Ipilimumab 治疗转移性眼葡萄膜黑色素瘤：一项评估未测量混杂因素对观察性关联影响 E 值敏感性分析”

Clinical Drug Investigation

IF2.7

2025-10-28

OAAI

Claire Watkins; Luis del Carpio; Josep M. Piulats

Abemaciclib plus abiraterone in patients with metastatic castration-resistant prostate cancer (CYCLONE 2): a randomised, double-blind, placebo-controlled, phase 3 trial 阿贝西利布联合阿比特龙在转移性去势抵抗性前列腺癌患者中的研究（CYCLONE 2）：一项随机、双盲、安慰剂对照、Ⅲ期临床试验

The Lancet Oncology

IF0

2025-10-27

PREAI

Matthew Smith; Josep Piulats; Tilman Todenhöfer; Jae-Lyun Lee; José Arranz Arija; Laura Mazilu; Arun Azad; Teresa Alonso-Gordoa; Ursula McGovern; Atish Choudhury; Lisa Horvath; Dingwei Ye; Weiqing Han; Hiroyoshi Suzuki; Hiroji Uemura; Rana McKay; Steven Ades; Aude Fléchon; Christopher Pieczonka; Maria S Fernandes; Maarten Hulstijn; Andrew Lithio; Karim Nacerddine; Neeraj Agarwal

Final overall survival and safety analyses of the phase 3 PSMAfore trial of [177Lu]Lu-PSMA-617 versus change of androgen receptor pathway inhibitor in taxane-naive patients with metastatic castration-resistant prostate cancer [177Lu]Lu-PSMA-617与雄激素受体途径抑制剂变化的PSMAfore 3期试验在未接受紫杉烷治疗的转移性去势抵抗性前列腺癌患者中的最终总生存期和安全性分析

Annals of Oncology

IF65.4

2025-07-17

OAAI

K. Fizazi; K.N. Chi; N.D. Shore; K. Herrmann; J.S. de Bono; D. Castellano; J.M. Piulats; A. Fléchon; X.X. Wei; H. Mahammedi; G. Roubaud; M. Fleming; T. Haas; S. Ghebremariam; T.N. Kreisl; S. Rajagopalan; O. Sartor; M.J. Morris

Molecular determinants of survival in metastatic uveal melanoma: The impact of SF3B1 mutations 转移性葡萄膜黑色素瘤生存的分子决定因素: SF3B1突变的影响

European Journal of Cancer

IF7.1

2025-06-24

PREAI

Luis P. del Carpio; Mar Varela; Mikel Portu; Sergi Villatoro; Elvira Purqueras; Montserrat Gomà; Daniel Lorenzo; Laura Lladò; Cristina Gutierrez; Emilio Ramos; Josep M. Caminal; Josep M. Piulats

Pembrolizumab plus enzalutamide and androgen deprivation therapy versus placebo plus enzalutamide and androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: the randomized, double-blind, phase III KEYNOTE-991 study☆帕博利珠单抗联合恩扎卢胺和雄激素剥夺疗法与安慰剂联合恩扎卢胺和雄激素剥夺疗法治疗转移性激素敏感性前列腺癌：随机、双盲、III期KEYNOTE-991研究☆

Annals of Oncology

IF65.4

2025-05-16

PREAI

C. Gratzke; M. Özgüroğlu; A. Peer; M.A.N. Sendur; M. Retz; J.C. Goh; W. Loidl; G. Jayram; S.-S. Byun; C. Kwak; M. Kwiatkowski; R. Manneh Kopp; J.C.V. Limón; J.F.E. Penagos; U. De Giorgi; K.M. da Trindade; C. Niu; Y. Liu; C.H. Poehlein; J.M. Piulats

Safety of adoptive therapy with tumor-infiltrating lymphocytes and high-dose recombinant interleukin 2 in advanced cutaneous melanoma: a systematic review and meta-analysis 使用肿瘤浸润淋巴细胞联合高剂量重组白细胞介素2进行过继治疗在晚期皮肤黑色素瘤中的安全性：一项系统评价和Meta分析

Annals of Oncology

IF65.4

2025-04-08

PREAI

S. Martín-Lluesma; U. Dafni; K. Vervita; D. Karlis; G. Dimopoulou; Z. Tsourti; G. Villacampa; V. Galvao; J. Lostes; E. Muñoz-Couselo; M. Rotxés; X. Villalobos; S. Muñoz; J.B.A.G. Haanen; I.M. Svane; J.M. Piulats; J. Martin-Liberal; A. Gros; G. Coukos; E. Garralda

Whole-body Magnetic Resonance Imaging as a Treatment Response Biomarker in Castration-resistant Prostate Cancer with Bone Metastases: The iPROMET Clinical Trial 全身磁共振成像作为去势抵抗性前列腺癌骨转移的治疗反应生物标志物: iPROMET临床试验

EUROPEAN UROLOGY

IF25.2

2024-09-01

PREAI

Garcia-Ruiz, Alonso; Macarro, Carlos; Zacchi, Francesca; Morales-Barrera, Rafael; Grussu, Francesco; Casanova-Salas, Irene; Sanguedolce, Francesco; Gonzalez, Macarena; Cresta-Morgado, Pablo; de Albert, Matias; Garcia-Bennett, Josep; Marmolejo, David; Planas, Jacques; Roche, Sarai; Mast, Richard; Zatse, Christina; Piulats, Josep M.; Herrera-Imbroda, Bernardo; Regis, Lucas; Agundez, Laura; Olmos, David; Calvo, Nahum; Escobar, Manuel; Carles, Joan; Mateo, Joaquin; Perez-Lopez, Raquel

177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial 177Lu-PSMA-617与雄激素受体途径抑制剂治疗的变化对紫杉烷初治的进行性转移性去势抵抗性前列腺癌患者 (PSMAfore): 一项3期随机对照试验

LANCET

IF88.5

2024-09-01

PREAI

Morris, Michael J.; Castellano, Daniel; Herrmann, Ken; de Bono, Johann S.; Shore, Neal D.; Chi, Kim N.; Crosby, Michael; Piulats, Josep M.; Flechon, Aude; Wei, Xiao X.; Mahammedi, Hakim; Roubaud, Guilhem; Studentova, Hana; Nagarajah, James; Mellado, Begona; Montesa-Pino, Alvaro; Kpamegan, Euloge; Ghebremariam, Samson; Kreisl, Teri N.; Wilke, Celine; Lehnhoff, Katja; Sartor, Oliver; Fizazi, Karim

Clinical protocol phase II study of tumor infiltrating lymphocytes in advanced tumors with alterations in the SWI/SNF complex: the TILTS study

FUTURE ONCOLOGY

IF2.6

2024-08-12

PREAI

Martin-Liberal, Juan; Garralda, Elena; Garcia-Donas, Jesus; Soto-Castillo, Juan Jose; Mussetti, Alberto; Codony, Carles; Martin-Lluesma, Silvia; Munoz, Susana; Galvao, Vladimir; Lostes, Julia; Rotxes, Marta; Prat-Vidal, Cristina; Palomero, Jara; Munoz, Ainhoa; Moreno, Rafael; del Muro, Xavier Garcia; Sureda, Anna; Alemany, Ramon; Gros, Alena; Piulats, Josep Maria

Cancer cell plasticity defines response to immunotherapy in cutaneous squamous cell carcinoma

NATURE COMMUNICATIONS

IF15.7

2024-06-24

OAAI

Lorenzo-Sanz, Laura; Lopez-Cerda, Marta; da Silva-Diz, Victoria; Artes, Marta H.; Llop, Sandra; Penin, Rosa M.; Bermejo, Josep Oriol; Gonzalez-Suarez, Eva; Esteller, Manel; Vinals, Francesc; Espinosa, Enrique; Oliva, Marc; Piulats, Josep M.; Martin-Liberal, Juan; Munoz, Purificacion

Pembrolizumab and Enzalutamide in Patients with Abiraterone Acetate-Pretreated Metastatic Castration-Resistant Prostate Cancer: Cohort C of the Phase 1b/2 KEYNOTE-365 Study Pembrolizumab和恩扎鲁他胺治疗经醋酸阿比曲酮预处理的转移性去势抵抗性前列腺癌患者: 1b/2期KEYNOTE-365研究的队列C

EUROPEAN UROLOGY ONCOLOGY

IF9.3

2024-06-01

OAAI

Yu, Evan Y.; Berry, William R.; Gurney, Howard; Retz, Margitta; Conter, Henry J.; Laguerre, Brigitte; Fong, Peter C. C.; Ferrario, Cristiano; Todenhofer, Tilman; Gravis, Gwenaelle; Piulats, Josep M.; Emmenegger, Urban; Shore, Neal D.; Romano, Emanuela; Mourey, Loic; Li, Xin Tong; Poehlein, Christian H.; Schloss, Charles; Appleman, Leonard J.; Bono, Johann S. de

Pembrolizumab plus Abiraterone Acetate and Prednisone in Patients with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Results from KEYNOTE-365 Cohort D 帕博利珠单抗联合阿比特龙醋酸盐和泼尼松用于化疗初治转移性去势抵抗性前列腺癌患者：KEYNOTE-365研究D队列的结果

European Urology Oncology

IF9.3

2024-06-01

OAAI

Evan Y. Yu; Cristiano Ferrario; Mark D. Linch; Michael Stoeckle; Brigitte Laguerre; Jose A. Arranz; Tilman Todenhöfer; Peter C. Fong; Josep M. Piulats; William Berry; Urban Emmenegger; Loic Mourey; Anthony M. Joshua; Nataliya Mar; Leonard J. Appleman; Henry J. Conter; Gwenaelle Gravis; Xin Tong Li; Charles Schloss; Christian Poehlein; Johann S. de Bono

A phase II study (AARDVARC) of AZD4635 in combination with durvalumab and cabazitaxel in patients with progressive, metastatic, castration-resistant prostate cancer

ESMO OPEN

IF8.3

2024-06-01

OAAI

Alonso-Gordoa, T.; Goodman, M.; Vulsteke, C.; Roubaud, G.; Zhang, J.; Parikh, M.; Piulats, J. M.; Azaro, A.; James, G. D.; Cavazzina, R.; Gangl, E. T.; Thompson, J.; Pouliot, G.; Kumar, R.; Sweeney, C.

Merkel-cell carcinoma: ESMO-EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up 默克尔细胞癌: esmo-euracan诊断，治疗和随访的临床实践指南

ESMO OPEN

IF8.3

2024-05-01

OAAI

Lugowska, I.; Becker, J. C.; Ascierto, P. A.; Veness, M.; Blom, A.; Lebbe, C.; Migliano, E.; Hamming-Vrieze, O.; Goebeler, M.; Kneitz, H.; Nathan, P.; Rutkowski, P.; Slowinska, M.; Schadendorf, D.; Piulats, J. M.; Petrelli, F.; van Akkooi, A. C. J.; Berruti, A.

TMPRSS2-ERG and RB1 as candidate predictive biomarkers for efficacy in TALAPRO-2: Phase 3 study of talazoparib (TALA) plus enzalutamide (ENZA) vs placebo (PBO) plus ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

CANCER RESEARCH

IF16.6

2024-04-05

PREAI

Piulats, Josep M.; Azad, Arun A.; Laird, A. Douglas; Matsubara, Nobuaki; Fizazi, Karim; Shore, Neal D.; Karsh, Lawrence; Liu, Glenn; Fay, Andre P.; Carles, Joan; Jones, Robert J.; Voog, Eric; Zschabitz, Stefanie; De Giorgi, Ugo; Yip, Steven M.; Mu, Xinmeng Jasmine; Lin, Xun; Engelsberg, Arne; Agarwal, Neeraj

Identification of a novel agnostic predictive multiomic signature via Elastic Net/Machine Learning in TALAPRO-2 ( TP-2), a phase 3 study of talazoparib (TALA) plus enzalutamide (ENZA) vs placebo (PBO) plus ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

CANCER RESEARCH

IF16.6

2024-04-05

PREAI

Liu, Glenn; Mu, Xinmeng Jasmine; Fizazi, Karim; Laird, A. Douglas; Matsubara, Nobuaki; Yip, Steven M.; Pu, Jie; Carles, Joan; Fay, Andre P.; Jones, Robert J.; Zschaebitz, Stefanie; Piulats, Josep M.; Joung, Jae Young; Roh, Whijae; Chelliserry, Jijumon; Di Santo, Nicola; Saul, Michelle; Azad, Arun A.; Agarwal, Neeraj

Overall survival from tebentafusp versus nivolumab plus ipilimumab in first-line metastatic uveal melanoma: a propensity score-weighted analysis 一线转移性葡萄膜黑色素瘤中tebentafusp与nivolumab联合ipilimumab的总生存率: 倾向评分加权分析

ANNALS OF ONCOLOGY

IF65.4

2024-03-01

OAAI

Piulats, J. M.; Watkins, C.; Costa-Garcia, M.; del Carpio, L.; Piperno-Neumann, S.; Rutkowski, P.; Hassel, J. C.; Espinosa, E.; de la Cruz-Merino, L.; Ochsenreither, S.; Shoushtari, A. N.; Orloff, M.; Salama, A. K. S.; Goodall, H. M.; Baurain, J. -F.; Nathan, P.

研究方向